Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*

(2010) Todd W. Rice et al.   CRITICAL CARE MEDICINE

Toll-like Receptor 4 Modulation as a Strategy to Treat Sepsis

(2010) X. Wittebole et al.   MEDIATORS OF INFLAMMATION

Protective Effects of Toll-like Receptor 4 Inhibitor Eritoran on Renal Ischemia-Reperfusion Injury

(2010) M. Liu et al.   TRANSPLANTATION PROCEEDINGS

Identification of pediatric septic shock subclasses based on genome-wide expression profiling

(2009) Hector R Wong et al.   BMC Medicine

The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis

(2009) P.C. Minneci et al.   CLINICAL MICROBIOLOGY AND INFECTION

Risk of death and the efficacy of eritoran tetrasodium (E5564): Design considerations for clinical trials of anti-inflammatory agents in sepsis*

(2009) Amisha V. Barochia et al.   CRITICAL CARE MEDICINE

Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*

(2009) Mark Tidswell et al.   CRITICAL CARE MEDICINE

Inhibition of Corneal Inflammation by the TLR4 Antagonist Eritoran Tetrasodium (E5564)

(2009) Y. Sun et al.   INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

Therapeutic approach to regulate innate immune response by Toll-like receptor 4 antagonist E5564 in rats with D-galactosamine-induced acute severe liver injury

(2009) Toshiyuki Kitazawa et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Salvage effect of E5564, Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats

(2009) Toshiyuki Kitazawa et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex

(2009) Beom Seok Park et al.   NATURE

Protection from lethal Gram-negative bacterial sepsis by targeting Toll-like receptor 4

(2009) T. Roger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers

(2008) Daniel P. Rossignol et al.   Innate Immunity

Once is not enough: clinical trials in sepsis

(2008) Daniel A. Sweeney et al.   INTENSIVE CARE MEDICINE